Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States
about
Infectious MononucleosisSystemic Epstein-Barr virus-positive T/natural killer-cell lymphoproliferative disorder: a case report and review of literatureAltered antibody profiles against common infectious agents in chronic diseaseThe Epstein-Barr Virus (EBV) in T Cell and NK Cell Lymphomas: Time for a Reassessment.Epstein-Barr Virus-Associated Lymphoproliferative Disorders: Review and Update on 2016 WHO Classification.Clinicopathological characteristics of four cases of EBV positive T-cell lymphoproliferative disorders of childhood in China.XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus.X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia disease: a combined immune deficiency with magnesium defect.Luciferase immunoprecipitation systems for measuring antibodies in autoimmune and infectious diseases.EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management.Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines.Deciphering the role of Epstein-Barr virus in the pathogenesis of T and NK cell lymphoproliferationsHigh Viral Loads of Epstein-Barr Virus DNA in Peripheral Blood of Patients with Chronic Lymphocytic Leukemia Associated with Unfavorable Prognosis.Late-onset severe chronic active EBV in a patient for five years with mutations in STXBP2 (MUNC18-2) and PRF1 (perforin 1).The Cancer-Associated Virus Landscape in HIV Patients with Oral Hairy Leukoplakia, Kaposi's Sarcoma, and Non-Hodgkin Lymphoma.Epstein-Barr virus Latent Membrane Protein 2A (LMP2A)-mediated changes in Fas expression and Fas-dependent apoptosis: Role of Lyn/Syk activation.Epstein-Barr virus-associated inflammatory pseudotumor presenting as a colonic massNo serological evidence for a role of HHV-6 infection in chronic fatigue syndrome.Viral-associated lymphoid proliferations.Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers.Searching for biomarkers: humoral response profiling with luciferase immunoprecipitation systems.Early lesions in lymphoid neoplasia: Conclusions based on the Workshop of the XV. Meeting of the European Association of Hematopathology and the Society of Hematopathology, in Uppsala, Sweden.Emerging concepts in haematopoietic cell transplantation.The Putative Role of Viruses, Bacteria, and Chronic Fungal Biotoxin Exposure in the Genesis of Intractable Fatigue Accompanied by Cognitive and Physical Disability.Severe Epstein-Barr virus infection in primary immunodeficiency and the normal host.T- and NK-Cell Lymphomas and Systemic Lymphoproliferative Disorders and the Immunodeficiency Setting: 2015 SH/EAHP Workshop Report-Part 4.Recent advances in understanding Epstein-Barr virus.The diagnosis and management of NK/T-cell lymphomas.2016 WHO Classification update-What's new in lymphoid neoplasms.Emerging insights on the pathogenesis and treatment of extranodal NK/T cell lymphomas (ENKTL).An unusual presentation of a common infection.Unusual Indolent Course of a Chronic Active Epstein-Barr Virus-Associated Natural Killer Cell Lymphoproliferative Disorder.A case of hypersensitivity to mosquito bites without peripheral natural killer cell lymphocytosis in a 6-year-old Korean boy.Treatment choice of immunotherapy or further chemotherapy for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.Aggressive peripheral CD70-positive T-cell lymphoma associated with severe chronic active EBV infectionFavorable outcome of Epstein-Barr virus-associated B-cell lymphoproliferative disorder complicated by immunoglobulin G4-related disease treated with rituximab-based therapy: a case report.Small-cell predominant extranodal NK/T cell lymphoma, nasal type: clinicopathological analysis of a series of cases diagnosed in a Western population.Chronic active Epstein-Barr virus infection with cutaneous and sinus lymphoproliferation in a white female patient with 25 years' follow-up: an original case report.Epstein-Barr virus persistence and reactivation in neuromyelitis optica.Chronic active Epstein-Barr virus infection with cutaneous lymphoproliferation: haemophagocytosis in the skin and haemophagocytic syndrome.
P2860
Q26783692-5903AA8B-4B54-438A-8D04-55A71824C93FQ26998815-511DEBC5-BE2D-4A8B-813B-8F55ED57D735Q28661374-957DB0CE-555F-437F-A62E-B6DA13832462Q30278553-8E9E00A7-6709-4C63-9A68-7B56967B9831Q33925581-E0BCCE12-6F79-4771-B93F-EC18144F3B37Q34121469-DF7A03BA-348A-425C-AD95-CC1E8976106DQ34405170-58A9BECE-464C-4A8C-B51D-2B9CEDF744D4Q35011670-25128D24-7095-4DA9-9A0B-F4572D5B24D9Q35013894-9DC62295-7D96-43D9-B2FB-D9B4DB5F8A54Q35040644-20A8ED4B-2217-496A-A5FA-891FF97687DEQ35115666-2A0995DE-14C5-4FD8-A516-A4573E584504Q35232848-75093E39-49C1-4A04-8B70-40663777F036Q35804493-8D61E625-F16A-4B75-80D1-ACFEAD837FF6Q35858526-EA83F493-401B-4885-91B1-328693C0C023Q36178032-720D55A1-0ADD-44F7-9961-A9B5CF8B718BQ36199894-22AD1BF6-B893-4472-8D16-BB788F606D8AQ36296448-1CB6F0D0-CCAA-42EF-A6B5-757C0F7EC65EQ36383086-014E725D-C297-418F-B6CA-D951B5C26BFCQ36941309-B7FA56AB-3F05-4E7D-A22E-4BCA57537941Q36991772-9857738C-DCD0-415C-87A8-5EA45A9D83DDQ37281501-E7CEADA1-FF1E-489A-AA5C-3A4A7CA1CCE4Q37352773-7FB00B0E-AF21-4826-8455-CECA2BB727AEQ38013047-F1FCD3D0-5C09-440E-BE47-DA3F4E9EB095Q38529622-857003AD-E7F5-4356-9C74-08851308A56CQ38982455-46892C1A-AA3F-41A1-B6F4-F4823FD36749Q39232117-FB6CAF53-9C92-48DD-86A2-97082619AD42Q39241944-6D1F2BE0-FD9E-438A-8352-0E03AE25EA6EQ39243241-89146BBF-3B09-4A4E-8199-FFB0BC304DA7Q39266295-8DFEA543-F55D-4455-8920-E1EC914629C8Q39284101-8E2C820F-D090-4E9B-BED4-E94682DBA4A9Q39397490-A0B9CBA8-F4C1-4D50-9D86-5836106AC479Q40104117-52223921-9C0C-4816-80C3-7CB261BFE015Q40259979-83A9930D-EFEE-4791-9393-ADA6835D4638Q40302112-AC5BEFA1-6D26-49B3-A12A-76E71499C372Q40406380-BD8D11AA-525A-4CB1-BA07-3B4CA07B5040Q40564284-A31CED70-0BA8-409C-83AD-D38A64CBA7EBQ40688247-597A671B-571C-49C9-B895-671E71F02378Q41120745-DF244D17-22AE-47BF-A4E4-629536EBF3F1Q41644226-BB621D93-255D-4B66-8648-435BB255DC9CQ41918112-363A4D28-155E-47F8-86EA-83FFDCB05B23
P2860
Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Characterization and treatment ...... xperience in the United States
@ast
Characterization and treatment ...... xperience in the United States
@en
Characterization and treatment ...... xperience in the United States
@nl
type
label
Characterization and treatment ...... xperience in the United States
@ast
Characterization and treatment ...... xperience in the United States
@en
Characterization and treatment ...... xperience in the United States
@nl
prefLabel
Characterization and treatment ...... xperience in the United States
@ast
Characterization and treatment ...... xperience in the United States
@en
Characterization and treatment ...... xperience in the United States
@nl
P2093
P2860
P50
P3181
P1433
P1476
Characterization and treatment ...... xperience in the United States
@en
P2093
Alan S Wayne
Catherine M Bollard
Claude Sportes
Cliona M Rooney
Daniel Fowler
Helen E Heslop
Janet K Dale
Jeffrey I Cohen
Michael R Bishop
Mitchell S Cairo
P2860
P304
P3181
P356
10.1182/BLOOD-2010-11-316745
P407
P577
2011-03-31T00:00:00Z